The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.
(turmeric), and have received much attention due to their pleiotropic anticancer properties. Recent evidence suggests that curcumin and analogs prevent the activation of a variety of signaling pathways, including the MAPK, PI3K/Akt, and NF-kB pathways, resulting in the induction of apoptosis, prevention of proliferation, and suppression. In addition to these processes, curcumin has been shown to enhance the efficacy of the conventional anti-cancer modalities such as radiation and chemotherapy. By suppressing the expression of matrix metalloproteinases (MMPs), which are enzymes that break down the extracellular matrix and promote cancer cell invasion and metastasis, curcumin also demonstrates anti-metastatic qualities. Inflammation and the advancement of cancer are linked to the NF-κB signaling pathways, which are also suppressed by curcuminoids. Along with these processes, curcumin has demonstrated the ability to improve the effectiveness of traditional cancer treatments, including radiation and chemotherapy. It increases the sensitivity of cancer cells to various therapies, which enhances the therapeutic results. However, curcumin's low bioavailability limits its therapeutic use. Its anticancer potency may be increased, and this restriction may be overcome due to recent developments in drug delivery technologies, such as curcumin-loaded nanoparticles. Since they can target several different molecular pathways and improve the effectiveness of current treatments, curcuminoids are a promising family of chemicals for the prevention and treatment of cancer.
Libyan Journal of Medicine · vol. 21 (1) · 2681841-2681841
Folk medicine remains an important component of health practices in Saudi Arabia and continues to attract growing scholarly attention. This study maps the scholarly landscape of folk medicine research related to Saudi Arabia by examining publication trends, author keywords, collaboration among institutions and countries, and the impact of authors and sources. Publications were retrieved from the Scopus and Web of Science databases using Saudi Arabia as the country affiliation. After PRISMA-guided identification, screening, deduplication, and eligibility assessment, 2527 publications published between 1989 and 2024 were retained for analysis. Bibliometrix was used for bibliometric computation and visualization, and VOSviewer was used to map country co-authorship and keyword co-occurrence networks. The results show sustained growth in publication output, strong participation by Saudi institutions, and broad international collaboration. The most prominent research themes were antioxidant activity, antimicrobial properties, herbal medicine, and traditional medicine. These findings provide a bibliometric overview of knowledge production in this area and may inform future systematic, clinical, and policy-oriented research on traditional medicine in Saudi Arabia.
folk medicinetraditional medicineSaudi Arabiaherbal medicine
This study reports the isolation, structural elucidation, and biological evaluation of a novel naphthofuran derivative (compound 1), methyl 9-methoxy-4-methylnaphtho[1,2-c]furan-3-carboxylate, along with known compounds; chrysophanol (2) and 2-acetyl-1,8-dimethoxy-3-methylnaphthalene (3) from the aerial parts of Asphodelus microcarpus. The structure was established by 1D/2D NMR and HR-ESI-MS. Compound 1 exhibited potent bactericidal activity against MRSA ATCC 3345 (MIC = 3.13 μg/mL, MBC = 12.5 μg/mL, MBC/MIC = 4) and significant dose-independent antibiofilm activity (maximum inhibition 64.7 ± 0.35% at MIC). Computational studies including ligand-based similarity searching, molecular docking, hydration site analysis, and 500 ns molecular dynamics simulations identified dihydrofolate reductase (DHFR) as a potential target, with compound 1 showing favorable binding (ΔG_bind = −55.13 kcal/mol) driven by π–π stacking with Phe92—a selectivity-determining residue absent in human DHFR (Val115). Comparative docking predicted ~20-fold selectivity for bacterial DHFR. In silico ADMET profiling revealed full drug-likeness compliance with no PAINS or toxicity alerts. Compound 1 represents the first naphthofuran from A. microcarpus with a computationally defined mechanism, positioning it as a promising anti-MRSA lead.
Advanced Health Science and Technology Journal · vol. 2 (1) · 21-26
Abstract Aspirin is one of the oldest and most used anti-platelet medications for the prevention of cardiovascular diseases. There has been conflicting research recently about how body weight affects the antiplatelet effectiveness of aspirin. The purpose of this narrative review was to examine the recent research on the connection between aspirin responsiveness, platelet function, and obesity. To find patterns and discrepancies, pertinent research from PubMed, Scopus, and Google Scholar was rigorously examined and compiled. While some studies showed no discernible effect, others highlighted methodological and population-specific variations by reporting decreased aspirin efficacy in people with higher body weight because of increased platelet reactivity, aspirin deactivation, and altered pharmacokinetics, underscoring the need for well-designed, large-scale clinical investigations. The need for carefully planned, extensive clinical studies is highlighted by the fact that the evidence is still equivocal overall. A better understanding of these mechanisms may support the development of personalized antiplatelet strategies, including tailored aspirin dosing in selected subgroups such as obese patients with high thrombotic risk.
Luteolin is widely distributed phytochemical, a flavonoid, in kingdom plantae. Luteolin with potential antioxidant activity prevent ROS-induced damages and reduce oxidative stress which is mainly responsible in pathogenesis of many diseases. Several chemo preventive activities and therapeutic benefits are associated with luteolin. Luteolin prevents cancer via modulation of numerous pathways, that is, by inactivating proteins; such as procaspase-9, CDC2 and cyclin B or upregulation of caspase-9 and caspase-3, cytochrome C, cyclin A, CDK2, and APAF-1, in turn inducing cell cycle arrest as well as apoptosis. It also enhances phosphorylation of p53 and expression level of p53-targeted downstream gene. By Increasing BAX protein expression; decreasing VEGF and Bcl-2 expression it can initiate cell cycle arrest and apoptosis. Luteolin can stimulate mitochondrial-modulated functions to cause cellular death. It can also reduce expression levels of p-Akt, p-EGFR, p-Erk1/2, and p-STAT3. Luteolin plays positive role against cardiovascular disorders by improving cardiac function, decreasing the release of inflammatory cytokines and cardiac enzymes, prevention of cardiac fibrosis and hypertrophy; enhances level of CTGF, TGFβ1, ANP, Nox2, Nox4 gene expressions. Meanwhile suppresses TGFβ1 expression and phosphorylation of JNK. Luteolin helps fight diabetes via inhibition of alpha-glucosidase and ChE activity. It can reduce activity levels of catalase, superoxide dismutase, and GS4. It can improve blood glucose, insulin, HOMA-IR, and HbA1c levels. This review is an attempt to elaborate molecular targets of luteolin and its role in modulating irregularities in cellular pathways to overcome severe outcomes during diseases including cancer, cardiovascular disorders, diabetes, obesity, inflammation, Alzheimer's disease, Parkinson's disease, hepatic disorders, renal disorders, brain injury, and asthma. As luteolin has enormous therapeutic benefits, it could be a potential candidate in future drug development strategies.
ABSTRACT Anthocyanins (Anthos; flower and kyanos; blue) are natural coloring compounds from the flavonoids class that include cyanidin, peonidin, delphinidin, malvidin, pelargonidin, and petunidin. Recently, the role of anthocyanins in disease prevention, especially inflammation, diabetes, cancer, neuro‐disorders, hepato‐renal protective, and immuno‐modulation properties has been highlighted. The current review covered the literature on the pharmacokinetics and pharmacological effects of anthocyanins, especially absorption, distribution, metabolism, and excretion (ADME). The discussion on molecular mechanisms underlying their therapeutic effects is the limelight of the article. The GLUT1, GLUT3, SGLT1, SMCT1, and SMCT2 are the main carriers involved in the transportation of anthocyanins in the gastrointestinal tract. The anthocyanins exert their anticancer effects by reducing the expression of IL‐6, IL‐1β, TNF‐β, COX‐2, downregulation of NF‐kB, EZH2, MDR1, Akt , and modulation of P13K/AKT and AMPK/mTOR pathways. The reduction in α‐amylase and α‐glucosidase and improved FFAR1 activity results in antidiabetic effects. The regulation of PGC‐1α/NRF2/TFAM, p‐PI3K/Akt/GSK3β, and Nrf2/HO‐1 prevents neurodegeneration. The anthocyanins impose hepato‐renal protective effects via ameliorating NLRP3 inflammasome, inhibiting MDA, GSSG, iNOS, HO‐1, ICAM‐1, β2‐microglobulin, and MPO activity, and improved SOD, CAT, and GSH activity. Anthocyanins promote beneficial gut microbiota and enhance SCFA production, thus inhibiting pro‐inflammatory markers. The immuno‐modulatory impact of anthocyanins involves the reduction of CRP, P‐selectin, C1q, and C4. Anthocyanins reduce LDL, VLDL, TGs, and TC via improved GBA and upregulation of ATP6 V0C, ZO‐1, and ATG4D expression. The WHO/FAO suggested that 2.5 mg/kg/day of grape‐skin extracts of anthocyanins are safe, and China recommended that 50 mg/day of anthocyanins are safe for consumption. In a nutshell, the multifaceted health benefits of anthocyanins make them promising candidates for disease prevention and therapeutic interventions.
The continuous progression of cancerous severity due to the interaction of physical (ultraviolet radiation), chemical (smoking, mycotoxins, and heavy metals), and biological (microbial populations) carcinogens inspired scientists to develop a correlation between active therapeutic agents and cancer proliferation. This review highlights the molecular mechanism by which lycopene imparts its anticancerous role, focusing on clinical and animal trials to validate its effectiveness. The antioxidant profile of lycopene promotes anticancerous properties that reduce cancer prevalence by activating cell signaling pathways and gene expression (involved in cancer cell proliferation). Lycopene's anti-inflammatory properties suppresses the tumor growth and development-promoting pathways, such as the PI3K/Akt/mTOR pathway. The anticancer property of lycopene is also evidenced by its inhibitory potential of the Wnt/β-catenin signaling pathway that is involved in cancer cell modulation and propagation. Lycopene also suppresses and neutralizes oxidative stress and reactive oxygen species (ROS)-induced DNA damage, preventing gene mutation. Inflammation-induced cell death is mitigated by lycopene's anti-inflammatory potential that lowers the expression of interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Several clinical and randomized control trials have revealed the effect of lycopene supplementation in the management of cancer, including breast cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, skin cancer, oral cancer, liver cancer, gastric cancer, and kidney cancer, by lessening prostate-specific antigen (PSA) levels. These studies also accentuate certain limitations that need further trials to evaluate the long-term consequences of lycopene supplementations and their specific effective dose.
The recent approval of the nasal spray combination of mometasone (MOM) and olopatadine (OLO) presents a significant analytical challenge, as only a single reported method exists for its determination, deviating from eco-friendly practices. This study addresses this critical gap by pioneering the application of machine learning techniques to develop robust UV spectrophotometric approach for the simultaneous quantification of MOM and OLO, along with two genotoxic impurities: 4-dimethylamino pyridine (DAP) and methyl para-toluene sulfonate (MTS). By simultaneously determining these highly concerning genotoxic impurities and active pharmaceutical ingredients, this method underscores its paramount significance in upholding rigorous pharmaceutical quality standards and safeguarding patient safety. Applying the multilevel-multifactor experimental design, the calibration set was meticulously chosen at five different concentrations, yielding 25 calibration mixtures with central levels of 4, 46.5, 2.5, and 3 µg/mL for MOM, OLA, MTS, and DAP, respectively. The key innovation lies in the strategic implementation of the Kennard-Stone Clustering Algorithm to create a robust validation set of thirteen mixtures, resolving the limitations of reported chemometric methods' random data splitting. This approach ensures unbiased evaluation across the full concentration space, improving the method's reliability and sustainability. The robustness of this approach was rigorously tested using five distinct chemometric models: principal component regression, classical least squares, partial least squares, genetic algorithm-partial least squares, and multivariate curve resolution-alternating least squares, demonstrating its broad applicability across diverse modeling techniques. All models successfully determined all components with excellent recovery, low bias-corrected prediction, and adequate limits of detection. The Greenness Index Spider Charts and the Green Solvents Selection Tool were used to choose environmentally conscious solvents. A comprehensive sustainability assessment employed six state-of-the-art tools, including the national environmental method index, complementary green analytical procedure index, analytical greenness metric, blue applicability grade index, carbon footprint analysis, and the red-green-blue 12 metrics. Favorable results across all metrics affirmed the method's eco-friendliness, real-world applicability, and cost-effectiveness, supporting sustainable development goals in pharmaceutical quality control processes.
Human physiology is a complex process encompassing various biochemical mechanisms, regulated by hundreds of chemical mediators, thus making it more complicated to understand. Balance between these mediators is mandatory to continue the helm of life; however, an imbalance can disrupt normal physiological functions and lead to chronic health conditions. Cancer is one such chronic state that occurs due to an imbalance or overproduction of reactive oxygen and nitrogen species (RONS), which are highly unstable and damage other chemical constituents in the body. The mutilation at the cellular level results in DNA and genetic mutation, uncontrolled cell proliferation, metastasis, organ dysfunction, and ultimately mortality. Various types of cancers are intimidating human life globally, and lung cancer is leading them all, followed by breast and colorectal cancer. Oxidative stress (OS) is the main root cause of cancers that occur due to overproduced RONS. Tumor suppressor genes (TSGs) like p53, PTEN, INK4, MADR2, APC, and oncogenes such as HER2, BCR/ABL1, CMYC, EML4AK, RAS, WNT, ERK, and TRK get mutated by OS. Moreover, various pro-inflammatory markers i.e., IL-1, IL-6, TNF-α, IFN-γ, TGF-β and growth factors (VEGF, EGF, IGF-2) are also involved in cancer progression. Along with these aspects, the oncogenesis involves different signaling pathways/axis such as MAPK, PI3K, mTOR, Wnt/β-catenin, GSK3, and NF-κB. Epigallocatechin gallate (EGCG), a bioactive compound abundantly existing in green tea and grapes with strong antioxidant activity and anticancer potential, is a suitable approach to reduce the cancer burden. The in vitro and in vivo anticancer studies of EGCG proved anticancer and anti-tumor effects through modulation of cancer signaling pathways, reduction in cell proliferation, decreased metastasis, suppressed angiogenesis, enhanced antioxidant activity, inhibited pro-inflammatory biomarkers, improved TSGs expression, and downregulated oncogenes expression. Shortly, the current review focuses on the anticancer potential of EGCG through possible mechanisms.
Punicalagin, being a bioactive polyphenol, has gained significant interest owing to its potential anticancer effects. Researchers are studying punicalagin to determine its ability to inhibit cancer cell proliferation. This paper focuses on highlighting the therapeutic potential of punicalagin against tumors and cancers. Punicalagin inhibits tumor growth within the body through various cellular pathway interactions. This compound effectively eliminates tumor cells from the liver, stomach, prostate, and lungs. Different animal model studies have demonstrated the potential of punicalagin in blocking the MAPK/ERK and PI3K/AKT/mTOR signaling pathways, fighting against cancer. Through the inhibition of cell division, punicalagin may be capable of eradicating breast cancer cells. Punicalagin strongly inhibits the activities of vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and uPA. Punicalagin effectively inhibits the androgen receptor (AR), a protein essential for the development and metastasis of prostate cancer. Lung cancer cells can be eliminated by initiating the caspase cascade and inhibiting protein synthesis, which is facilitated by punicalagin. In numerous animal models, punicalagin significantly reduces metastasis. Cyclokinase B1 and cyclin-dependent kinase 2 promote colon cancer; when colon cancer cells reach the G2/M phase, punicalagin induces apoptosis by inhibiting the action of these proteins. Punicalagin inhibits tumor development and cancer propagation by inhibiting blood vessel proliferation. There is still a need for further clinical trials and studies to fully reveal punicalagin's potential as well as its safety; despite the fact that it may decrease the threat of increasing tumors and provide an alternative treatment for many cancers.